Skip to main content
  • Book
  • © 2022

Cardiovascular Complications of COVID-19

Risk, Pathogenesis and Outcomes

Authors:

(view affiliations)
  • Reveals the emerging literature and presents an overview of COVID-19 from a cardiovascular perspective

  • Highlights the main epidemiological, virological, pathogenetic and clinical features of COVID-19

  • Compiles state of the art information derived from the most recent evidence from COVID-19 research

Buying options

eBook
USD 119.00
Price excludes VAT (USA)
  • ISBN: 978-3-030-90065-6
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
Hardcover Book
USD 159.99
Price excludes VAT (USA)

This is a preview of subscription content, access via your institution.

Table of contents (20 chapters)

  1. An Overview of Quality of Research in COVID19

    • Umair Mallick
    Pages 395-409
  2. Back Matter

    Pages 411-414

About this book

This book discusses the evidence behind the relationship between COVID-19 and heart disease based on emerging state-of-the-art data. The rapid and unexpected global spread of the COVID-19 has revealed proportional levels of cardiovascular and metabolic complications. A myriad of pathogenetic mechanisms has come to the surface. There is still much research required to define whether cardiovascular disease causes COVID-19 complications or that cardiovascular disease appears as a result of the infection and which mechanisms are responsible. With cardiovascular and metabolic diseases already at pandemic levels and expected to increase further, this book provides readers with an urgent and thorough analysis of this association.

Cardiovascular Complications of COVID-19: Risk, Pathogenesis and Outcomes provides answers to the increasing numbers of questions related to heart disease in COVID-19, highlighting the association between these pandemics and including risk factors, mechanisms and how these may impact diverse patients populations. It describes how COVID-19 impacts older patients and those with metabolic illnesses such as obesity and diabetes mellitus, while providing an overview of the observed gender dichotomy among patients. It therefore represents an essential resource not only for all cardiovascular physicians but also for any healthcare professionals managing patients with these diseases or those exploring COVID-19.

Keywords

  • Heart disease
  • Cardiac injury
  • Inflammation
  • ACE2 inhibitors
  • COVID-19
  • Cardiovascular disease in COVID-19

Authors and Affiliations

  • Kingston Hospital NHS Foundation Trust London, London, UK

    Umair Mallick

About the author

Dr. Umair Mallick is a consultant cardiologist with an international portfolio in academic and industrial clinical research. He has made significant contributions to science and the medical fields internationally by serving clinical and healthcare institutions, academia, the pharmaceutical industry, and actively engaging in multiple important research initiatives and collaborations globally.

His clinical expertise includes complex hypertension, heart failure, stroke, and cardiovascular disease prevention, and has a special interest in the older age population. He has held several positions as a clinician and clinical researcher in prestigious world-class academic, and healthcare institutions including the National Health Services (NHS) of the United Kingdom and Europe, as well as pharmaceutical industrial institutions. He has served as an advisor and member of panels for several national and international academic organizations, has peer-reviewed for highly ranking prestigious medical journals, and has published in the field of cardiology, metabolic diseases, and clinical trials.

Dr. Mallick has designed and led various initiatives for the improvement of the quality of care of patients, education programs and clinical care pathways, research protocols, and clinical guidelines. He has advanced level expertise in designing, conducting, and analysis of large international complex clinical trials, and epidemiological studies, and has served in key areas of the drug discovery process, including collaboration with ethics and regulatory bodies in the domain of clinical research.

At present, he is the Director at Heart Health and Research International (HHRI) Ltd and ad hoc consultant with NHS hospitals in the United Kingdom. 

Bibliographic Information

  • Book Title: Cardiovascular Complications of COVID-19

  • Book Subtitle: Risk, Pathogenesis and Outcomes

  • Authors: Umair Mallick

  • DOI: https://doi.org/10.1007/978-3-030-90065-6

  • Publisher: Springer Cham

  • eBook Packages: Medicine, Medicine (R0)

  • Copyright Information: The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG 2022

  • Hardcover ISBN: 978-3-030-90064-9

  • eBook ISBN: 978-3-030-90065-6

  • Edition Number: 1

  • Number of Pages: X, 414

  • Number of Illustrations: 18 b/w illustrations, 69 illustrations in colour

  • Topics: Cardiology, Public Health, Epidemiology

Buying options

eBook
USD 119.00
Price excludes VAT (USA)
  • ISBN: 978-3-030-90065-6
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
Hardcover Book
USD 159.99
Price excludes VAT (USA)